Background: Oxygen desaturation during walking can have important consequence on prognosis of COPD patients. However, a standard 6-min walk test (6MWT), useful in detecting desaturation in COPD patients, can be difficult to execute in some settings of COPD management, as in the community healthcare service. We evaluated a new scoring system for the risk of oxygen desaturation during walking in COPD patients: the walking desaturation score.

Methods: We collected data from symptomatic COPD in-patients admitted for rehabilitation (derivation cohort) and out-patients referred to the local community health service (validation cohort). S(pO2) was monitored during 6MWT, and the subjects were classified as walking desaturators or non-desaturators. By a regression analysis model we assigned a weighted score proportional to the measured percentage of explained variance for each variable. Risk estimates were computed as odds ratios. A receiver operating characteristic curve analysis and a Hosmer-Lemeshow goodness-of-fit test were then performed to measure discrimination and calibration of walking desaturation score.

Results: Baseline characteristics in the derivation cohort (n = 435, 74% of whom were walking desaturators) and the validation cohort (n = 238, 37% of whom were walking desaturators) were different. Resting arterial oxygen saturation measured from an arterial blood sample, P(aO2), and percent-of-predicted FEV1 were the variables that predicted walking desaturation. The proportion of walking desaturators (and odds ratio estimate) gradually increased according to walking desaturation score (range 0-6) and associated categories of desaturation risk (total walking desaturation score: low 0 or 1, high 2-3, very high 4-6) (chi-square P < .001). There was considerable predictive discrimination (area under the curve 0.90, 95% CI 0.86-0.93, P < .001), and calibration (Hosmer-Lemeshow chi-square 1.31, P = .86) values have been shown.

Conclusions: Walking desaturation score accurately predicts and classifies the risk of walking desaturation in COPD patients. ClinicalTrials.gov Number NCT01303913.

Download full-text PDF

Source
http://dx.doi.org/10.4187/respcare.02321DOI Listing

Publication Analysis

Top Keywords

walking desaturation
28
copd patients
20
walking desaturators
16
walking
13
desaturation score
12
desaturation
11
oxygen desaturation
8
desaturation walking
8
desaturation copd
8
derivation cohort
8

Similar Publications

Background: COVID-19 vaccines reduced mortality, hospitalizations and ICUs admissions. Conversely, the impact of vaccination on Long COVID-19 syndrome is still unclear. This study compared the prevalence of post-acute sequelae at short and long-term follow-up among hospitalized unvaccinated and vaccinated COVID-19 survivors through a multidisciplinary approach.

View Article and Find Full Text PDF
Article Synopsis
  • Ambulatory oxygen is vital for patients with idiopathic pulmonary fibrosis (IPF) and chronic obstructive pulmonary disease (COPD) who have low oxygen levels during physical activity, especially if traditional testing may miss their true needs.
  • A study reviewed treadmill exercise tests for 329 IPF patients and 2,343 COPD patients to measure their oxygen flow requirements, finding that IPF patients typically need more oxygen than COPD patients at peak exertion.
  • Notably, while some patients didn't need oxygen during moderate exercise, a significant portion (49% of IPF and 24% of COPD patients) required it when pushed to their highest level of exertion, highlighting the limitations of standard testing.
View Article and Find Full Text PDF
Article Synopsis
  • Pulmonary rehabilitation (PR) was implemented for COVID-19 patients experiencing long-term effects to assess its impact on their functional capacity and health-related quality of life (HRQOL).
  • The study involved 155 post-COVID patients undergoing a pre and post-assessment that included a six-minute walk test, focusing on various interventions like education, exercise, and strength training, conducted over eight weeks.
  • Results indicated significant improvements in resting pulse rate, oxygen saturation, walking distance, and various HRQOL domains, highlighting PR as effective for enhancing the quality of life in post-COVID patients.
View Article and Find Full Text PDF

Introduction: Fibrotic interstitial lung diseases (ILD) are a heterogeneous group of conditions. Progression criteria include clinical, imaging, and/or lung functional decline. Currently, the 6-min walk test (6MWT) is considered the gold standard for assessing exercise-induced desaturation.

View Article and Find Full Text PDF

Safety of Nintedanib in a Patient with Chronic Pulmonary Fibrosis and Kidney Disease.

Pharmaceuticals (Basel)

August 2024

Pulmonology Unit, Department of Medical Surgical and Health Sciences, University of Trieste, Hospital of Cattinara, 34149 Trieste, Italy.

Nintedanib, an intracellular inhibitor that targets multiple tyrosine kinase, is an important drug for the treatment of pulmonary fibrosis. Until now, no studies have been published reporting the nintedanib tolerability or its efficacy in patients with chronic pulmonary lung disease and chronic kidney disease comorbidity. The safety, efficacy and pharmacokinetics of nintedanib have not been studied in patients with severe renal impairment (creatinine clearance < 30 mL/min) and for this reason it is contraindicated in these patients.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!